Skip to main content
Clinical Trials/NCT04792710
NCT04792710
Unknown
Phase 4

Randomised Trial Comparing Pre-operative Administration of Single Dose Kefazolin to Kefazolin Plus Metronidazole to Reduce Postpartum Infection

University of Pretoria1 site in 1 country1,000 target enrollmentMarch 8, 2021

Overview

Phase
Phase 4
Intervention
Metronidazole
Conditions
Prevention of Postpartum Sepsis
Sponsor
University of Pretoria
Enrollment
1000
Locations
1
Primary Endpoint
Efficacy of reducing surgical site infection
Last Updated
5 years ago

Overview

Brief Summary

Randomised controlled trial to investigate the efficacy of adding metronidazole pre-operatively to kefazolin in reducing postpartum infection

Detailed Description

All pregnant patients scheduled for emergency or elective Caesarean section ≥18 years, willing and able to provide informed consent and not receiving antibiotics, will be eligible for recruitment. Patients will be randomised into receiving kefazolin according to current standard of care administered pre-operatively intravenously with placebo (control arm), and kefazolin according to current standard of care administered pre-operatively with metronidazole 500 mg intravenously pre-operatively. Outcome measures will be surgical site infection, urinary tract infection and postpartum endometritis. Five hundred patients will be recruited in each arm

Registry
clinicaltrials.gov
Start Date
March 8, 2021
End Date
June 30, 2022
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Leon Snyman

Prof

University of Pretoria

Eligibility Criteria

Inclusion Criteria

  • 18 years and older Willing and able to provide written informed consent

Exclusion Criteria

  • women younger than 18 years women not able or willing to provide written informed consent women with or without infection already receiving antibiotics for other indications women allergic to kefazolin or metronidazole

Arms & Interventions

Intervention arm

This arm will be allocated to receive metronidazole 500 mg in addition to the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section as a once off dose

Intervention: Metronidazole

Control arm

This arm will be allocated to receive the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section plus a placebo of normal saline 50 ml administered intravenously as a once off dose

Intervention: Metronidazole

Outcomes

Primary Outcomes

Efficacy of reducing surgical site infection

Time Frame: Seven days post-operatively

Incidence of surgical site infections

Secondary Outcomes

  • Efficacy of reducing urinary tact infections(Three days post-operatively)
  • Efficacy of reducing postpartum endometritis(Seven days post-operatively)

Study Sites (1)

Loading locations...

Similar Trials